abediterol (AZD-0548) / Almirall, AstraZeneca - LARVOL DELTA

AstraZeneca drops breast, prostate cancer programs in Q4 pipeline cull (FierceBiotech) - "The fourth-quarter pipeline update also saw AstraZeneca drop velsecorat, a selective glucocorticoid receptor modulator that it was developing as a treatment for asthma and chronic obstructive pulmonary disease (COPD). AstraZeneca said it dropped the program for strategic reasons. Another asthma and COPD candidate, abediterol, landed on the scrapheap for the same reasons."

Discontinued • Asthma • Chronic Obstructive Pulmonary Disease • Respiratory Diseases

Ultra-LABAs for the treatment of asthma. (PubMed, Respir Med) - "The term ultra-LABA indicates once-daily β2-AR agonists (abediterol, indacaterol, olodaterol and vilanterol) that are single enantiomers of the (R)-configuration. The once-daily posology might increase adherence in long-term treatment of asthma but superiority to twice-daily LABAs has not yet been fully demonstrated. In any case, still no ultra-LABA can be recommended as preferred."

Journal • Review • Asthma • Respiratory Diseases

Relative Bioavailability Study With Abediterol Administered Via Three Different Inhalation Devices in Healthy Volunteers. (clinicaltrials.gov) - P1; N=25; Terminated; Sponsor: AstraZeneca; Recruiting ➔ Terminated; The decision to terminate has been taken by the Sponsor. The decision is not due to safety concerns but reflects business prioritizations of the company.

Clinical • Trial termination • Chronic Obstructive Pulmonary Disease • Pulmonary Disease • Respiratory Diseases • CRP

Relative Bioavailability Study With Abediterol Administered Via Three Different Inhalation Devices in Healthy Volunteers. (clinicaltrials.gov) - P1; N=32; Recruiting; Sponsor: AstraZeneca; Not yet recruiting ➔ Recruiting

Clinical • Enrollment open • CRP

Relative Bioavailability Study With Abediterol Administered Via Three Different Inhalation Devices in Healthy Volunteers. (clinicaltrials.gov) - P1; N=32; Not yet recruiting; Sponsor: AstraZeneca

Clinical • New P1 trial